


**Supplemental Materials to:**

**Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor  
effectors without autoimmunity**

Gabriele Cantini, Federica Pisati, Sara Pessina, Gaetano Finocchiaro and Serena Pellegatta

OncoImmunology 2012; 1(8); DOI: 10.4161.onci.20637


**Figure S1. GLAST-peptide administration increased significantly peripheral immune cells**



In cervical lymph nodes from immunized mice the percentage of CD4, CD8-T and NK cells increased significantly when compared to controls: A. CD4<sup>+</sup>  $23.50 \pm 2.10$  vs.  $15.20 \pm 0.10$ , p = 0.04; CD8<sup>+</sup> cells  $13.60 \pm 1.40$  vs.  $5.10 \pm 0.70$ , p = 0.01; B. CD3<sup>-</sup> NKp46<sup>+</sup> cells  $2.00 \pm 0.50$  vs.  $0.20 \pm 0.07$ , p = 0.01 immunized vs. vehicle mice respectively.

The panels show representative dot plots obtained from three different evaluations 15 days after tumor implantation.

**Figure S2. Nestin/GLAST double positive cells disappeared in gliomas from immunized mice**



- A. Gliomas from control mice treated with vehicle investigated 22 days after tumor implantation showed high levels of nestin (red) and GLAST (green) double positive cells.
- B. In gliomas from mice immunized with GLAST peptides and sacrificed on day 22 double positive cells disappeared.

Three representative mice for each group have been investigated and representative images are displayed.

## **Sequences of primers for SYBR® Green Chemistry**

**b2m:** fw 5'-GAATGGGAAGCCGAACATAC-3';

rev 5'-CCGTTCTTCAGCATTGGAT-3'

**IFN- $\gamma$ :** fw 5'-ATCTGGAGGAACTGGCAAAA-3'

rev 5'-TTCAAGACTTCAAAGAGTCTGAGGTA-3'

**TNF- $\alpha$ :** fw 5'-GCCACCACGCTCTGTCTA-3'

rev 5'-TGAGGGTCTGGGCCATAGAA-3'

**TGF- $\beta$ :** fw 5'-CTAATGGTGGACCGCAACAAC-3'

rev 5'-GCACTGCTTCCGAATGTCT-3'

**Granzyme B:** fw 5'-GCTGCTCACTGTGAAGGAAGT-3'

rev 5'-TGGGGAATGCATTTCACCAT-3'

**E4BP4:** fw 5'-AAAACAACGAAGCTGCCAAA-3'

rev 5'-CCAAAACCAGGTCATTGAGG-3'

**CD49d:** fw 5'-CAAACCAGACCTGCGAAC-3'

rev 5'- TGTCTTCCCACAAGGCTCTC-3'

**CXCL10:** fw 5'-GCTGCCGTCAATTCTGC-3'

rev 5'-TCTCACTGGCCCGTCATC-3'

**CCL5:** fw 5'-CCCTCACCATCATCCTCACT-3'

rev 5'-GAGAGGTAGGCAAAGCAGCA-3'

**CCL2:** fw 5'-CATCCACGTGTTGGCTCA-3'

rev 5'-GATCATCTGCTGGTGAATGAGT-3'

**CCL4:** fw 5'-GCCCTCTCTCCTCTTGC-3'

rev 5'-GAGGGTCAGAGCCCATTG-3'

**CCL3:** fw 5'-CAAGTCTTCTCAGCGCCATA-3'

rev 5'-GGAATCTTCCGGCTGTAGG-3'

**NKG2DL:** fw 5'-TGAAGTCACCTGTGTTATGCAG-3'

rev 5'-CACTGTCAAAGAGTCATCCAACA-3'